Wird geladen...

Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury

A screen by Kost-Alimova et al.(1) suggests that the FDA-approved SYK inhibitor fostamatinib inhibits MUC1 in the respiratory tract and has the potential to treat serious outcomes of coronavirus COVID-19, including acute respiratory distress syndrome (ARDS) and acute lung injury (ALI).

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cell Rep Med
Hauptverfasser: Tabassum, Neha, Zhang, Hua, Stebbing, Justin
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2020
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7670931/
https://ncbi.nlm.nih.gov/pubmed/33225317
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xcrm.2020.100145
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!